Can Amgen's MariTide Disrupt the GLP-1 Obesity Market? A Deep Dive into Dosing and Cardiometabolic Edge

The GLP-1 obesity drug market, now a $180 billion juggernaut by 2034 projections, has become a battleground for biotech giants. Novo Nordisk and Eli Lilly dominate with semaglutide (Wegovy) and tirzepatide (Zepbound), respectively, but Amgen's MariTide-a once-monthly or less frequently dosed peptide-antibody conjugate-has emerged as a potential disruptor. With Phase II data showcasing robust weight loss and cardiometabolic benefits, the question looms: Can Amgen leverage differentiated dosing and broader therapeutic claims to challenge the status quo?

MariTide's Phase II Results: A New Benchmark in Weight Loss and Tolerability

Amgen's Phase II trial results for MariTide (maridebart cafraglutide) reveal a compelling profile. Participants without Type 2 diabetes (T2D) achieved an average 20% weight loss over 52 weeks, while those with T2D lost 17%-outpacing many existing GLP-1 therapies. Notably, these results were sustained without a weight loss plateau, a common limitation in chronic obesity treatment. Additionally, MariTide demonstrated significant cardiometabolic improvements: HbA1c dropped by up to 2.2% in T2D patients, alongside reductions in waist circumference, blood pressure, and inflammation (as measured by high-sensitivity C-reactive protein, or hs-CRP).

Gastrointestinal tolerability, a persistent hurdle for GLP-1 drugs, also showed promise. By employing lower starting doses with gradual escalation, MariTide reduced the frequency and severity of GI events, particularly during initial treatment. This approach aligns with patient-centric design, addressing a key unmet need in the market.

Dosing Frequency: A Strategic Differentiator

The most striking advantage of MariTide lies in its dosing regimen. While Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) require weekly injections, and Novo's oral semaglutide demands daily administration, MariTide's once-monthly or less frequent dosing could revolutionize adherence and patient satisfaction. In a market where treatment persistence is critical, reducing the burden of frequent injections or pills may tilt preferences toward Amgen's offering.

Eli Lilly currently holds a 57% market share in Q2 2025, driven by Zepbound's superior weight loss and tolerability compared to Wegovy. However, its weekly dosing regimen remains a barrier for some patients. Novo Nordisk, meanwhile, is racing to launch an oral semaglutide formulation by year-end 2025 according to industry sources, but daily compliance challenges persist.

MariTide's monthly dosing could bridge this gap, offering a middle ground between efficacy and convenience.

Cardiometabolic Benefits: Expanding the Therapeutic Horizon

Beyond weight loss, MariTide's cardiometabolic profile positions it to address broader metabolic comorbidities. The drug's ability to reduce HbA1c, hs-CRP, and blood pressure aligns with the growing recognition of obesity as a systemic disease. Clinical evidence from Eli Lilly's SELECT trial has already established semaglutide's 20% reduction in major adverse cardiovascular events according to market analysis, but MariTide's Phase III program (MARITIME) is explicitly evaluating outcomes in atherosclastic cardiovascular disease, heart failure, and obstructive sleep apnea as reported in Amgen's press release.

This expanded indication strategy mirrors Novo Nordisk's and Eli Lilly's moves into metabolic associated steatohepatitis (MASH) and peripheral artery disease according to industry insights. However, Amgen's focus on less frequently dosed regimens could capture a niche market of patients seeking fewer injections while addressing cardiovascular risk-a dual benefit that resonates with both clinicians and payers.

Market Dynamics: Can Amgen Close the Gap?

Despite MariTide's strengths, Amgen faces formidable competition. Eli Lilly's aggressive DTC campaigns (e.g., Lilly Direct for Zepbound) and Novo Nordisk's NovoCare program for Wegovy have streamlined access and affordability. Both companies have also secured manufacturing capacity expansions, resolving past supply constraints. For example, Novo Nordisk's $4.1 billion fill-finish plant and Eli Lilly's $5.3 billion active pharmaceutical ingredients facility underscore their commitment to scaling production as reported in industry forecasts.

Yet Amgen's differentiation lies in its ability to combine once-monthly dosing with robust cardiometabolic data-a combination that could attract patients dissatisfied with current options. The Phase III MARITIME program, which includes trials in diverse populations (with and without T2D), will be pivotal in validating these claims according to Amgen's press release. Additionally, Amgen's planned studies in cardiovascular disease and heart failure could unlock new revenue streams by positioning MariTide as a first-line therapy for multimorbid patients.

Investment Outlook: A Calculated Bet on Innovation

The GLP-1 market's projected 23.1% CAGR through 2035 ensures ample room for disruption. While Eli Lilly and Novo Nordisk dominate today, Amgen's MariTide offers a compelling value proposition: superior dosing convenience, validated weight loss, and expanding cardiometabolic indications. However, success hinges on Phase III replication of Phase II results and effective commercialization strategies.

For investors, the key risks include regulatory delays, competition from oral GLP-1s, and pricing pressures. Yet, if MariTide secures approval and gains traction in the $180 billion market, Amgen could carve out a significant niche-particularly in cardiovascular and heart failure indications where current therapies fall short.